P‐044: Accurate and early detection of Alzheimer's disease using a gene expression signature in blood

Lönneborg, Anders; Booij, Birgitte; Jensen, Mette Munk; Sharma, Pradeep; Bårdsen, Ken; Hagen, Nina; Kristiansen, Lena; Lindahl, Torbjørn; Sæbø, Solve; Feten, Guri; Winblad, Bengt; Iqbal, Khalid; Sharma, Praveen

doi:10.1016/j.jalz.2007.04.260

Cited by 2 publications

(5 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of 27 samples with Parkinson's disease, 24 were correctly predicted as non-AD. 43 In this model, more than 1,200 gene probes were used. A selection of these gene probes has been converted to gene assays and used in studies using RT-PCR instead of microarray hybridisation.…”

Section: Rnamentioning

confidence: 99%

“…The number of gene assays in the model has been reduced to fit within a 96-assay format without significantly reducing the accuracy (81%). 43 This approach, using the expression pattern from many informative genes, has the potential to cover more of the multifactorial nature of AD than existing single or double biomarkers.…”

Section: Rnamentioning

confidence: 99%

“…The multicomponent biomarkers using blood samples, such as the proteome 29 and transcriptome 43 approaches, show promise to function as biomarkers for AD. 30,46 The use of a set of 18 polypeptides or a set of fewer than 96 gene-expression assays show both high specificity and sensitivity and have the potential to simultaneously measure changes in several biological processes associated with AD.…”

Section: Biomarkers For the Futurementioning

confidence: 99%

“…A biomarker in blood would clearly be more widely applicable and reduce the need for invasive, expensive or time-consuming testing. Not surprisingly, the two latest approaches for multicomponent biomarker discovery and development 29,43 have chosen blood as the clinical sample, and it is expected that future development of clinically useful biomarkers for AD will focus on this strategy.…”

Section: Biomarkers For the Futurementioning

confidence: 99%

See 3 more Smart Citations

Blood Biomarkers for Alzheimer’s Disease

Winblad¹,

Lönneborg²

2008

European Neurological Review

Self Cite

View full text Add to dashboard Cite

Alzheimer's disease (AD) is a multifactorial and heterogeneous disease in both its clinical and histopathological appearance. In more than 99% of cases the cause of the disease is not understood. Independent of its cause, AD is clinically characterised by a developing dementia and histopathologically characterised by neuronal degeneration.Although the presence of neurofibrillary tangles (NFTs) and neurotic The development of biomarkers for AD is challenging as it is complicated by several factors. In addition to the variability in clinical features and multiple molecular aetiologies, the development of AD biomarkers is burdened with a diagnostic imprecision as confirmation of the disease preferentially has to await a post mortem histopathological examination.The long asymptomatic prodromal stages, rates of progression and complex disease genetics complicate the situation further. In this article we will review the current developments in the field of biomarkers for the detection of AD in blood. Single-component BiomarkersThe physiology of the blood-brain barrier limits potential biomarkers that are closely associated to brain pathophysiology to small molecules, lipophilic molecules and molecules with specific transporters. 12 Brainderived proteins and metabolites that pass into the plasma will also become markedly diluted in a biochemically complex medium. 12 Moreover, it is not known whether there are any direct pathophysiological processes associated with AD in blood cells. The traditional approach of using one or a few closely related molecules as a biomarker, a single-component biomarker, in plasma, serum or blood has been utilised since the late 1990s. [13][14][15] However, their usefulness has been limited, mainly due to discrepant results between studies. Amyloid β-proteinAβ can be detected in plasma and is thus a compelling candidate biomarker for AD. The plasma total Aβ or Aβ42 was increased in familial AD with presenilin or APP mutations 16,17 and in Down's syndrome with APP triplication, 18 which raises the possibility that sporadic AD may also be associated with detectable and diagnostic changes in Aβ plasma levels. Animal models suggest that Aβ can pass between cerebrospinal fluid (CSF) and plasma compartments, 19,20 but this has yet to be confirmed in humans. APP is also produced by platelets and is, therefore, an alternative source for the APP and Aβ pools found in plasma.

show abstract

Section: Rnamentioning

confidence: 99%

Section: Rnamentioning

confidence: 99%

Section: Biomarkers For the Futurementioning

confidence: 99%

Section: Biomarkers For the Futurementioning

confidence: 99%

See 2 more Smart Citations

Blood Biomarkers for Alzheimer’s Disease

Winblad¹,

Lönneborg²

2008

European Neurological Review

Self Cite

View full text Add to dashboard Cite

show abstract

“…33 Protein metabolism and modification markers as well as nucleoside, nucleotide, and nucleic acid metabolism signals have also been reported. 34 Recently, a profile of signaling proteins was culled from a larger exploratory study of AD cases and normal controls. 24 If the distinct genomic pattern of prevalent or incipient AD were known, it could be utilized for diagnosis and to justify the initiation of intervention strategies.…”

Section: Blood Biomarkersmentioning

confidence: 99%

Taking the Next Steps in the Diagnosis of Alzheimer's Disease: The Use of Biomarkers

DeKosky¹

2008

CNS Spectr.

View full text Add to dashboard Cite

Alzheimer's disease (AD) is a progressive disorder in which neurodegeneration begins decades before clinical symptoms appear. Detecting AD during this preclinical phase presents both the enormous challenge of identifying at-risk patients prior to symptom onset and the potential reward of treating patients early enough to prevent or slow disease progression. Given that a 5-year delay in the onset of the clinical manifestations of AD could result in almost a 50% reduction in disease prevalence, early detection of AD is a major focus of clinical research. Several objective, measurable indicators of preclinical and clinical characteristics of AD are currently available or in development. These biomarkers are promising because they promote identification of individuals at risk for AD onset and disease progression; diagnostic accuracy and treatment during the early stages of AD; and the development of disease-modifying therapies that may potentially slow or prevent disease progression during the preclinical phase of AD.

show abstract

P‐044: Accurate and early detection of Alzheimer's disease using a gene expression signature in blood

Cited by 2 publications

References 1 publication

Blood Biomarkers for Alzheimer’s Disease

Blood Biomarkers for Alzheimer’s Disease

Taking the Next Steps in the Diagnosis of Alzheimer's Disease: The Use of Biomarkers

Contact Info

Product

Resources

About